Ppars as metabolic integrators in pancreatic beta-cell. New challenges for the therapy of type 2 diabetes. A minireview

This is an automatically generated default intro template – please do not edit.

	Read full article
Article Title:	Ppars as metabolic integrators in pancreatic beta-cell. New challenges for the therapy of type 2 diabetes. A minireview
Authors:	Iuliana Ristea Popescu
Affiliation:	1 INSERM U1011, Institut Pasteur de Lille, 59800 Lille, France 2 Université libre de Bruxelles, Faculté de Médecine, Lab of Histology & Neuropathology, Brussels, Belgium
Abstract:
Keywords:
References:	Chuang J-C et al. Nuclear Hormone Receptor Expression in the Endocrine Pancreas. Mol Endocrinology; 22(10): 2353-2363, 2008 Díaz-Delfín J et al. Hypoglycemic action of thiazolidinediones/peroxisome proliferatoractivated receptor γ by inhibition of the c-Jun NH2- terminal kinase pathway. Diabetes; 56(7): 1865-71, 2007 Dubois M et al. Expression of peroxisome proliferatoractivated receptor γ (PPARγ) in normal human pancreatic islet cells. Diabetologia; 43: 1165 –1169, 2000 Evans-Molina C et al. Peroxisome proliferator-activated receptor gamma activation restores islet function in diabetic mice through reduction of endoplasmic reticulum stress and maintenance of euchromatin structure. Mol Cell Biol.; 29 (8): 2053-2067, 2009 Fagot – Gampagna A. and Narayan K. Type 2 diabetes in children. Br. Med. J.; 322: 377-378, 2001 Forman BM et al. Hypolipidemic drugs, polyunsaturated fatty acids and eicosanoids are ligands for peroxisome proliferator- activated receptors α and δ. Proc Natl Acad Sci U S A; 94:4312–4317, 1997 Frigerio F et al. Peroxisome proliferators-activated receptor alpha (PPARalpha) protects against oleateinduced INS-1E beta cell dysfunction by preserving carbohydrate metabolism. Diabetologia 2010; 53 (2): 331-340, 2010 Han SJ et al. Rosiglitazone inhibits early stage of glucolipotoxicity-induced β-cell apoptosis. Horm Res; 70(3): 165-73, 2008 Hellemans K et al. Peroxisome proliferator-activated receptor-alpha-retinoid X receptor agonists induce β-cell protection against palmitate toxicity. FEBS J 2007; 274(23): 6094-105, 2007 Ito E et al. PPARγ overexpression selectively suppresses insulin secretory capacity in isolated pancreatic islets through induction of UCP-2 protein. Biochem Biophys Res Commun; 324(2): 810-814, 2004 Jiang L et al. Activation of PPARdelta promotes mitochondrial energy metabolism and decreases basal insulin secretion in palmitate-treated β-cells. Mol Cell Biochem.; 343:249-256, 2010 Kanda Y. et al. Molecular mechanisms by which pioglitazone preserves pancreatic beta-cells in obese diabetic mice: evidence for acute and chronic actions as a PPARγ agonist. Am J Physiol Endocrinol Metab.; 298(2):E278-286, 2010 Kim HS et al. Rosiglitazone stimulates the release and synthesis of insulin by enhancing GLUT-2, glucokinase and Β2/NeuroD expression. Biochem Biophys Res Commun; 367(3): 623-9, 2008 Kim HI et al. Identification and functional characterization of the peroxisomal proliferator response element in rat GLUT2 promoter Diabetes; 49: 1517–1524, 2000 Kim HI et al. Peroxisomal proliferator-activated receptor γ upregulates glucokinase gene expression in β-cells. Diabetes; 51: 676 –685, 2002 Koh EH et al. Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-γ activation. Diabetes; 52: 2331–2337, 2003 Lalloyer F et al. Peroxisome proliferator-activated receptor α improves pancreatic adaptation to insulin resistance in obese mice and reduces lipotoxicity in human islets. Diabetes 2006; 55: 1605–1613, 2006 Lefebvre P. et al. Sorting out the roles of PPARα in energy metabolism and vascular homeostasis. J Clin Invest; 116 (3):571-580, 2006 Lupi R et al. Rosiglitazone prevents the impairment of human islet function induced by fatty acids: evidence for a role of PPARγ2 in the modulation of insulin secretion. Am J Physiol Endocrinol Metab; 286(4): E560-7, 2004 Nolan JJ et al. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone. N Engl J Med ; 331: 1188 –1193, 1994 Nolan CJ et al. Fatty acid signalling in the β-cell and insulin secretion. Diabetes; 55(Suppl. 2): S16-S23, 2006 Parvez H et al. Obesity and diabetes in the developing world – a growing challenge. N Engl J Med; 356(3): 213-215, 2007 Prentki M, et al. Malonyl-CoA signalling, lipid partitioning and glucolipotoxicity: role in β-cell adaptation and failure in the aetiology of diabetes. Diabetes 2002; 51(Suppl. 3): S405-S413, 2002 Prentki M, Nolan CJ. Islet β-cell failure in type 2 diabetes. J Clin Invest; 116 (7): 1802-1812, 2006 Ravnskjaer K et al. PPARdelta is a fatty acid sensor that enhanced mitochondrial oxidation in insulinsecreting cells and protects against fatty acidinduced dysfunction. J Lipid Re.; 51(6):1370-1379, 2010 Roduit R et al. Glucose down-regulates the expression of the peroxisome proliferator-activated receptoralpha gene in the pancreatic β-cell. J Biol Chem ; 275(46): 35799-806, 2000 Rosen ED et al. Targeted elimination of peroxisome proliferator-activated receptor γ in β-cells leads to abnormalities in islet mass without compromising glucose homeostasis. Mol Cell Biol 2003; 23(20): 7222-7229, 2003 Saitoh Y et al. Pioglitazone attenuates fatty acid-induced oxidative stress and apoptosis in pancreatic β-cells. Diabetes Obes Metab; 10(7): 564-573, 2008 Shannon M et al. PPAR delta as a therapeutic target in metabolic disease FEBS Lett.; 582(1): 26–31, 2008 Sun Y et al. Peroxisome proliferator-activated receptor α regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate. Endocrinology; 149(2): 662-71, 2008 Unger RH. and Zhou YT. Lipotoxicity of beta-cells in obesity and other causes of fatty acid spillover. Diabetes; 50: S118– S121, 2001 Wild S et al. Global Prevalence of Diabetes: Estimates for the year 2000 and projections for 2030. Diabetes Care; 27: 1047-1053, 2004 Winzell MS et al. Improved insulin sensitivity and islet function after PPARdelta activation in diabetic db/ db mice. Eur J Pharmacol.; 626(2-3): 297-305, 201 Zhou YT et al. Role of peroxisome proliferatoractivated receptor-alpha in disease of pancreatic β-cells. Proc Natl Acad Sci USA; 95: 8898–8903, 1998 Zhou YT et al. Role of peroxisome proliferator-activated receptor-alpha in disease of pancreatic β-cells. Proc Natl Acad Sci USA; 95: 8898–8903, 1998
*Correspondence:	Iuliana Ristea Popescu, Université libre de Bruxelles, Faculté de Médecine, Lab of Histology & Neuropathology, 808 Route de Lennik, B-1070 Brussels, Belgium, e-mail: ipopescu@ulb.ac.be